KULA 101

Drug Profile

KULA 101

Alternative Names: KULA101

Latest Information Update: 11 Dec 2015

Price : $50

At a glance

  • Originator Partikula
  • Class Small molecules
  • Mechanism of Action CD223 antigen inhibitors; CD4 antigen inhibitors; CD4-positive T lymphocyte stimulants; CD8 antigen inhibitors; CD8 positive T lymphocyte stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; HAVCR2 protein inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Dec 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top